Clinical Trial

A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to evaluate the safety and efficacy of GT729 universal cell injection in the treatment of refractory or relapsed chronic graft-versus-host disease (cGVHD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Trial Details
NCT Number NCT07253259
Lead Sponsor Grit Biotechnology
Collaborators: Institute of Hematology & Blood Diseases Hospital, China
Conditions cGVHD
Enrollment 36 participants
Start Date 2025-12-18
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-14